Verification of Dissolution Test for Doxycycline Hyclate in Capsules to Implement Into the Pharmacopoeial Monograph

The study of dissolution profiles is important as a cheap and easy supplement to bioequivalence research, and as a variation to such studies. This method is not outlined in the State Pharmacopoeia of Ukraine for the doxycycline capsules. Therefore, according to the current requirements, it was necessary to verify the procedure recommended by the US Pharmacopeia to confirm that this laboratory test will be reproduced correctly, and to use it in our further studies.The aim of our research was to verify the "Dissolution" test analytical procedure for doxycycline hyclate capsules, recommended by the US Pharmacopoeia.Methods. Capsules of doxycycline hyclate 100 mg and set of mineral waters were taken as study objects. A standard sample of doxycycline was used for preparation the comparison solutions. All reagents and test specimens meet the requirements of the SPhU. The experimental data were obtained at the same time in a standardized procedure. For this purpose, 9 points were studied within the range 55-135 % with a step of 10 %. The obtained results were processed statistically in accordance with the requirements of the SPhU.Results. The conducted prediction showed that the total uncertainty of the results of the methodic is 1.04 %, which does not exceed the critical value (3.0 %). To determine the specificity, the effect of placebo was investigated. The calculation showed that the overall effect of placebo on the total absorption of the drug is non-significant (0.51 % ≤ 0.96 %). Also, the method is linear in the range of concentrations from 55 % to 135 %. The systematic error of the results meets the recommended criteria.Conclusions. The analysis of model mixtures of doxycycline hyclate showed the correctness of the investigated metho

Development of the Method for Estimating Complex Formation Using the Electrochemical Impedance Spectroscopy on the Example of the Doxycycline and Iron (III) Interaction

The aim. To develop an EIS method for study the interaction between medicinal products and metal salts on the example of the Doxycycline and iron (III) interaction. Materials and methods. Measurements of the total impedance of the studied solutions have been performed using a vector circuit analyzer ZNB40 (Rohde & Schwarz, Germany). The calculations of electrical models were performed using the software package EC-Lab V10.40. Measurement cell was made of Teflon, 1 ml of volume, had 2 parallel nickel plated steel electrodes with diameter 6 mm, distance between electrodes is 9 mm. Basic electrical elements of model circuit were calculated according to type of electrochemical process that were described by Nyquist plot (RW, Rct, RS, Cd, CS etc.). Solutions were prepared immediately before the measurement. Measurements were performed at a temperature of 296±3 K. 6 control solutions of doxycycline and 6 control solutions of iron (III) chloride were prepared and measured. 11 study solutions at a molar ratio 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1 were prepared and measured. Concentration of the solutions was X∙10-3 mol/L respectively. Results. EIS analysis of Nyquist curves of study solutions in the range of molar ratios 1: 6, 1: 5, 1: 4, 1: 3, 1: 2, 1: 1, 2: 1, 3: 1, 4: 1, 5: 1, 6: 1 showed a change in the dynamics of electrical resistance at a ratio of 1:1. In the aqueous solution at T = 296±3 K the constant formation of the solution of doxycycline hyclate and iron (III) chloride is 2.9. This value of the complexation constant indicates that doxycycline hyclate forms a stable metal-ligand complex with iron (III) ions. Conclusions. EIS method can be applied to study the interaction of medicinal products. Model of this study was created on the example of doxycycline hyclate and iron (III) chloride. Metal-ion complexation of these two molecules was once again confirmed by using the EIS metho

Synthesis and Anticonvulsant Activity Evaluation of N-[(2,4-dichlorophenyl)methyl]-2-(2,4-dioxo-1h-quinazolin-3-yl)acetamide Novel 1-benzylsubstituted Derivatives

The aim. Synthesis of 1-benzylsubstituted derivatives of N-[(2,4-dichlorophenyl)methyl]-2-(2,4-dioxo-1h-quinazolin-3-yl)acetamide, and determination of affinity to GABAergic biotargets with the following anticonvulsant activity estimation using PTZ-induced seizures model in mice. Materials and methods. Standard organic synthesis methods were used; the structure of the synthesized compounds was proved by elemental analysis, 1H and 13C NMR spectroscopy, and LC/MS method; composition of the synthesized compounds – by elemental analysis, their individuality – by TLC and LC/MS methods. AutoDockTools-1.5.6, as well as AutoDock Vina software, was used to perform molecular docking. Anticonvulsant activity was studied using pentylenetetrazole-induced seizures in mice. Results. A targeted N-[(2,4-dichlorophenyl)methyl]-2-(1-(R-benzyl)-2,4-dioxo-quinazolin-3-yl)acetamides were obtained by alkylation of N-[(2,4-dichlorophenyl)methyl]-2-(2,4-dioxo-1H-quinazolin-3-yl)acetamide by corresponding 1-chloromethylbenzene in dimethylformamide environment with excess of potassium carbonate at a temperature 70-80 ˚С. Prediction of activity of 1-benzyl derivatives in the pentylenetetrazole-induced seizures in an in vivo experiment was carried out according to the obtained results of docking studies – affinity calculation for GABA receptor and GABA enzyme active sites, as well as analysis of conformational placement in them. In relation to the binding energy, the studied ligands were inferior to the reference drugs: GABA receptor positive allosteric modulators – benzamidine and diazepam, and GABA inhibitor – vigabatrin. The synthesized substances did not show anticonvulsant activity: only 2 compounds have shown a tendency to their activity manifestation according to the criterion of integral protective indicator – reduction of mortality by 17 % compared to control, as well as prolonging the time death of the animals. Comparison with the preliminary obtained results of the activity of the promising anticonvulsant N-[(2,4-dichlorophenyl)methyl] -2-(2,4-dioxo-1H-quinazolin-3-yl) acetamide N-[(2,4-dichlorophenyl)methyl]-2-(2,4-dioxo-1H-quinazolin-3-yl)acetamide made possible to prove the pharmacophore role of the cyclic amide fragment in anticonvulsant activity manifestation. Conclusion. The synthesis of N-[(2,4-dichlorophenyl)methyl]-2-(1-(R-benzyl)-2,4-dioxo-quinazolin-3-yl)acetamides, which have not still described in the literature, was carried out, as well as the structure of the mentioned compounds was proved. Unfortunately, the substances did not show anticonvulsant activity on the model of pentylenetetrazole-induced seizures. However, the obtained results allowed establishing the key role of the NHCO cyclic fragment on anticonvulsant activity. A positive correlation between the results of in vivo studies and in silico calculations was found – the model of pentylenetetrazole-induced seizures and docking into the active sites of PAMs GABAА receptor and enzyme inhibitor GABAАТ, which allows to recommend the given docking methodology as a tool to streamline and optimize the screening on the mentioned mode